A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Clinical trial NCT06680921 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06680921
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Locally Advanced or Metastatic Breast Cancer

Start date: 2024-11-14
Primary completion: 2028-08-31
Enrollment: 482

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.